

IN THE CLAIMS

1. (currently amended) A method of treating cancer pathologies and infectious pathologies comprising administering ~~Use of~~ chimeric, humanised or human class IgG3 monoclonal antibodyies produced in a cell line of rat myeloma, particularly YB2/0 (ATCC No. CRL 1662) or a derived or modified line of YB2/0 to a patient in need thereof. ~~for preparation of a medicine for the treatment of different cancer and infectious pathologies.~~

2. (currently amended) The method of claim 1, wherein said patient exhibits ~~Use according to claim 1, characterised in that it relates to patients with a~~ weak response to treatment with an IgG1 or an IgG3 expressed in CHO.

3. (currently amended) The method of claim 1, wherein said patient has ~~Use according to either claim 1 or 2, characterised in that it is used in patients with a~~ late diagnosis.

4. (currently amended) The method of claim 1, wherein ~~Use according to any one of the previous claims, characterised in that the said cancer pathologies are~~ selected from the group consisting of ~~chosen from among the group comprising~~ neuroectodermal tumours, colorectal cancers, melanomas, breast cancer, leukaemia and ~~partieularly~~ HCL (Hairy Cell Leukaemia), lymphomas such as DLBCL (Primary Diffuse Large B-Cell Lymphomas), acute leukaemias, and osteosarcomas.

5. (currently amended) The method of claim 1, wherein ~~said Use according to any one of the previous claims, characterised in that the said cancer pathologies are~~ associated with viral or bacterial infections.

6. (currently amended) The method of claim 5, wherein  
~~Use according to claim 5, characterised in that the said~~  
~~infections with viral or bacterial infections~~ origin are  
selected from the group consisting of ~~chosen from among the~~  
~~group comprising~~ cancer of the prostate, leukaemias, and  
Kaposi's sarcoma.

7. (currently amended) The method of claim 1, wherein  
~~Use according to any one of claims 1 to 3, characterised in that~~  
~~the said infectious pathologies are~~ selected from the group  
consisting of ~~chosen from the group including~~ diphtheria, viral  
hemorrhagic fevers, typhoid fever, influenza, hepatitis B and C,  
respiratory infections due to RSV, infections due to HIV,  
legionnaires' disease, Leishmaniasis, leprosy, rabies, AIDS ~~or~~  
and tuberculosis.

8. (currently amended) The method of claim 1, wherein  
~~Use according to any one of the previous claims, for the~~  
~~capability of the said antibody to induces~~ a phagocytosis.

9. (currently amended) The method of claim 1, wherein  
said antibody is produced in a cell line of rat myeloma,  
particularly YB2/0 (ATCC No. CRL 1662) or a derived or modified  
line of YB2/0 is ~~Use according to any one of the previous claims,~~  
~~characterised in that the said medicine is intended to be used~~  
administered to said patient in combination with an IgG1.

10. (currently amended) The method of claim 1, wherein  
said antibody ~~Use according to any one of the previous claims,~~  
~~for the capability of the said antibody to negatively modulates~~  
the release of cytokines induced by IgG1.

11. (currently amended) The method of claim 9, wherein said patient exhibits cancer pathologies consistent Use according to either claim 9 or 10, for the preparation of a medicine for the treatment of cancer pathologies in patients with a "cytokine release syndrome".

12. (currently amended) The method of claim 11, wherein said patient suffers from Use according to claim 11, for the preparation of a medicine to treat patients suffering from hypothermia, acute renal necrosis and/or a diseases of the liver due to the "cytokine release syndrome".

13. (currently amended) The method of claim 11, wherein the Use according to either claim 11 or 12, characterised in that the said "cytokine release syndrome" has been induced by the administration of an anti-CD3 monoclonal antibody.

14. (currently amended) The method of claim 11, wherein said patient has been treated with Use according to either claim 11 or 12, characterised in that the said class IgG3 monoclonal antibody is an anti-CD20, to which prevents the appearance of the "cytokine release syndrome" in patients treated with Rituximab® (IDEC C2B8).

15. (currently amended) The method of claim 11, wherein said antibody Use according to either claim 11 or 12, to prevents the undesirable effects of alemtuzumab the CAMPATH® or OKT3 antibody.

16. (currently amended) A method for Process for modulating the release of cytokines induced by an IgG1, wherein characterised in that IgG3s produced in a cell line of rat

myeloma, particularly YB2/0, are added to ~~the~~ a biological system containing ~~the~~ said IgG1s.

17. (currently amended) The method of claim 16, wherein ~~Process according to claim 16, characterised in that the said~~ IgG1s are produced in a cell line of rat myeloma, particularly YB2/0.

18. (currently amended) A Ppharmaceutical composition ~~comprising of therapeutic antibodies comprising~~ IgG1s, IgG3s and at least one excipient.

19. (currently amended) The composition of claim 18, ~~wherein Composition according to claim 18, characterised in that~~ at least one of ~~the said~~ IgG1s or IgG3s is produced in a rat myeloma cell line ~~of rat myeloma, and particularly YB2/0.~~

20. (new) The method of claim 10, wherein said antibodies negatively modulate the release of gamma IFN, alpha TNF and/or IL6 cytokines induced by IgG1.

21. (new) The composition of claim 19, wherein said at least one of said IgG1s or IgG3s is produced in the rat myeloma cell line YB2/0.